Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 190.3%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,878 shares, an increase of 190.3% from the February 12th total of 647 shares. Based on an average daily trading volume, of 32,271 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.1% of the company’s stock are sold short. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 32,271 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

BOLT has been the subject of a number of research analyst reports. Zacks Research cut Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $34.00.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ BOLT traded up $0.09 during mid-day trading on Thursday, hitting $4.22. The stock had a trading volume of 4,221 shares, compared to its average volume of 26,644. The firm has a market cap of $8.10 million, a PE ratio of -0.19 and a beta of 0.94. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57. The company has a 50 day moving average of $5.46 and a two-hundred day moving average of $5.37. Bolt Biotherapeutics has a twelve month low of $4.01 and a twelve month high of $9.66.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC lifted its stake in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares during the period. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics during the third quarter worth $85,000. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the third quarter worth $89,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Bolt Biotherapeutics during the fourth quarter valued at $112,000. Finally, Renaissance Technologies LLC boosted its holdings in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after purchasing an additional 26,400 shares during the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.